Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis

Abstract Background and Aim Vedolizumab is a humanized monoclonal antibody that selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa by antagonizing the interaction of α4β7 integrin with MAdCAM‐1. Vedolizumab is employed for ulcerative colitis with moderate t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daisuke Saito, Minoru Matsuura, Ryo Ozaki, Sotaro Tokunaga, Shintaro Minowa, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Mari Hayashida, Jun Miyoshi, Tadakazu Hisamatsu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-09-01
coleção:	JGH Open
Assuntos:	colonoscopy inflammatory bowel disease ulcerative colitis
Acesso em linha:	https://doi.org/10.1002/jgh3.12630
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!